LENZ LENZ Therapeutics, Inc.
P/E
--
Forward P/E
-1.19193
Price/Sales
4.755116
Beta
1.73
Div Yield
0.0%
Market Cap
--
Company Analysis
Latest News
LENZ Therapeutics third quarter 2026 revenue missed expectations as company announces 75% headcount reduction
LENZ Therapeutics reported third quarter 2026 total revenue of $3.4 million, missing the consensus estimate of $4.2 million. While the company achieved...
LENZ Therapeutics, Inc. Q3 2026 Earnings Preview: What Analysts Expect on October 29, 2026
For the third quarter of 2026, analysts expect LENZ Therapeutics to report revenue of $4.20 million and a consensus EPS of -$0.97, with the stock currently...